Hypofractionated Intensity Modulated Radiation Therapy Plus Hormonal Therapy in Patients With High Risk Prostate Cancer

Inclusion Criteria: * pathologically proven diagnosis of adenocarcinoma of the prostate meeting one of the following conditions: * Clinical Stage \>T3 or * Gleason Score 8 or higher, or * PSA level \>20ng/ml * Study entry PSA must be obtained within 6 weeks prior to protocol entry * ECOG \<2 * Age \>18 * History and physical examination within 3 months * Bone scan and CT scan of the abdomen and pelvis within 3 months with no evidence of bone metastases and no pelvic lymph nodes larger than 1.0cm, unless biopsy negative. * CBC with differential within 6 weeks prior to protocol entry * Absolute neutrophil count \>2000cells/mm3 * Hemoglobin \>8.0 g/dl (the use of transfusion to increase the Hg is acceptable) * Testosterone level within 6 weeks of protocol entry * Liver function tests * Signed informed consent * Prior use of hormonal therapy for prostate cancer is acceptable if less than 2 months. Exclusion Criteria: * Prior use of hormonal therapy for prostate cancer for more than 2 months. Previous use of finasteride or dutasteride is allowed. * Prior invasive malignancy (except non-melanoma skin) unless disease-free for more than 5 years. * Prior radiotherapy to the pelvis * Life expectancy of less than 2 years.